Although it came after our FY22 timeframe, the letter is worth mentioning because, in this case, the agency held the firm responsible for potentially causing downstream cGMP violations due to their inadequate testing methods
Abnormal results might mean a dose change, more frequent testing, additional tests, or stopping the drug
In addition, software-related technologies and any other applicable advanced technologies should be analyzed and utilized
In the randomized Semaglutide Treatment Effect in People with Obesity (STEP) 1 trial (intent to treat: 1,961 adults with overweight or obesity without T2D), once-weekly subcutaneous semaglutide 2.4 mg resulted in greater weight loss compared with placebo over a 68-week period (estimated treatment difference 12.4 percentage points, 95% confidence interval (CI) 13.4, 11.5
(4) Proline medium: MM medium supplemented with l-proline (10 mM) at pH 6.5
doi: 10.1080/15563650.2019.1579914 [PubMed] 31307590 Fisher ES, Curry SC